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ABSTRACT
Objective: To study the clinical, biochemical and radiological features and management outcomes of
patients with primary hyperparathyroidism.
Methods: This retrospective study was conducted at the Aga Khan University Hospital, Karachi, Pakistan
and comprised data of patients with primary hyperparathyroidism from 2008 to 2017.
Results: Out of 103 patients, 83(80.6%) were female. Overall mean age was 59.3±16.2 years. Musculoskeletal
manifestations were seen in 60(58.3%) patients and renal manifestations in 28(27.2%). Ostieits fibrosa
cystica was found in 04(3.88%) patients. Overall, Ultrasound neck and sestamibi scan localized the lesion
in 66 (64.1%) and 77 (76.2%) patients respectively. Among 79 patients who underwent surgery, 67 (84.8%)
patients had an adenoma, 05 (6.3%) had hyperplasia and 02(2.53%) patients had parathyroid carcinoma
whereas histopathology was inconclusive in 5 (6.32%) out of the 79 surgically treated patients. Disease
recurrence was seen in 13 out of 79(16.45%) patients who underwent surgery.
Conclusion: Primary hyperparathyroidism is associated with significant morbidity in our population.
Targeted measures like improving patient awareness, routine calcium screening, vitamin D supplementation
and a high index of suspicion by the clinician may help in early diagnosis of the condition and thus reduce
morbidity.
KEYWORDS: Primary Hyperparathyroidism, Hypercalcemia, Osteitis fibrosa cystica.
doi: https://doi.org/10.12669/pjms.36.6.2572

How to cite this:

Fatima T, Das B, Sattar S, Islam N. Primary Hyperparathyroidism: Experience from a Tertiary Care Centre in Pakistan. Pak J Med
Sci. 2020;36(6):1199-1203. doi: https://doi.org/10.12669/pjms.36.6.2572
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION
The prevalence and clinical presentation
of Primary Hyperparathyroidism (PHPT) is
strikingly different among populations.1-4 The
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difference is even more pronounced between
the West and the East. With the introduction
of routine calcium screening in the Western
world, the phenotype there has largely shifted
from symptomatic to asymptomatic and being
detected at early stages.5 Contrary to this, in the
developing countries, where there is no routine
screening of calcium, PHPT continues to present
as a symptomatic disease.6-9 Data from the
Rochester Epidemiological Project reported the
incidence of PHPT as 21.6 cases per 100000 person
years.1 There are very few studies regarding
PHPT in Pakistan and the exact prevalence in not
known.8-10 This study was designed to analyze
the clinical presentation, complications, and
management outcomes in patients with PHPT
in order to have a better understanding of the
disease spectrum in Pakistan.
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METHODS
This retrospective study was done after EC/
IRB approval (2019-0850-2587, Dated: 9 February
2019) at the Aga Khan University Hospital, a
tertiary Care Centre in Pakistan. This hospital is
located in Karachi and mainly caters to an urban
population. Data was collected from the medical
records of patients with PHPT from January
2008 to December 2017. This included patient
demographics, clinical presentation, laboratory
parameters such as Serum PTH and calcium at
presentation and on follow up after treatment,
serum phosphate, vitamin D, albumin, imaging,
treatment opted and histology. All calcium
values were corrected for respective albumin
concentrations. Diagnosis of PHPT was made on
the basis of hypercalcemia or normocalcemia with
high or inappropriately normal serum PTH levels.
All patients aged 18 years and above with PHPT
were included. Patients with renal failure and
hypercalcemia due to malignancy were excluded.
All clinical and radiological features and
management outcome of patients were reported
as frequency and percentages while biochemical
parameters were reported as mean with
Standard deviation (depending on the normality
assumption) or Median with Interquartile range (if
normality assumption was not met). Stata version
12 was used for analysis.
RESULTS
A total of 103 patients were identified with PHPT
from 1st Jan, 2008 till 31st Dec, 2017 with mean age
of 59.3±16.2 years. Majority of the patients were
female [83 (80.6%)]. Patients presented with various
clinical manifestations such as 60(58.3%) with
muscle and/or bone pain, 32(31.1%) with abdominal

Fig.1: Clinical manifestations of patients presenting
with primary hyperparathyroidism.
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pain and 28(27.2%) with renal manifestations.
Fragility fractures leading to difficulty in mobility
were seen in 13(12.6%) patients. Overall, 26(25%)
patients suffered with depression and headache in
23(22.3%) of patients (Fig.1). Total 40(39%) patients
had their DXA scan done out of which 31(30%) had
osteoporosis and 06 (5.8%) had osteopenia. Vitamin
D deficiency was found in 69(67%) patients. Ostieits
fibrosa cystica was found in 04 (3.9%) patients. None
of the patients had associated Multiple Endocrine
Neoplasia (MEN) syndrome.
Majority of the patients 79(76.7%) underwent
surgical treatment whereas, one fourth of patients
opted for medical treatment. Histology revealed
that 67(85%) out of those 79 patients had a
parathyroid adenoma, whereas hyperplasia was
seen in 05(6%) and carcinoma in 02(3%) patients.
Histology was not conclusive in 05(6%) out of the
79 patients who underwent surgery (refer to Fig.2).
On kidney ultrasound, 30 (29.1%) patients had renal
calculi and 01(0.98%) patient had nephrocalcinosiss.
Ultrasound neck and sestamibi scan were able
to localize the lesion in 66 (64.1%) and 77 (76.2%)
patients respectively.
Mean serum calcium levels were improved
post-surgery from 12.1 ± 1.8 mg/dl to 8.9 ± 0.8
mg/dl. Similarly, post-surgery PTH levels were
decreased from 653.6 ± 683.4 pg/ml to 61.1 ± 88.7
pg/ml (Table-I). Post-operative hypocalcemia
developed in 7 (8.8%) patients. Disease recurrence
as manifested by elevation of PTH on follow up
visit was seen in 13 (16.5%) out of the 79 patients
who underwent surgery.

Fig.2: Histological distribution of patients
with primary hyperparathyroidism.
n = Total number of Patients who underwent surgery.
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Table-I: Biochemical parameters of study participants.
Serum Calcium (mg/dl) (Pre-operative)
Serum Calcium (mg/dl) (Post-operative)
Serum PO4 (mg/dl)
Serum PTH (pg/ml) (Pre-operative)
Serum PTH (pg/ml) (Post-operative)
Serum Creatinine (mg/dl)
Serum Albumin (g/dl)
Vitamin D3 ng/ml

Normal Range

Means ± SD

Range (Min-Max)

8.1 - 10.4
8.1 - 10.4
2.5 - 4.8
16 - 81
16 - 81
0.5 - 1.2
3.5 - 5.2
Sufficiency>30

12.1 ± 1.8
8.9 ± 0.8
2.4 ± 0.8
653.6 ± 683.4
61.1 ± 88.7
0.8 ± 0.3
3.8 ± 0.7
23.4 ± 15.1

8.8 - 18.8
5.8 - 11.1
1 - 4.5
76 – 2500
3 – 575
0.3 - 1.9
2 - 5.2
4 – 101

DISCUSSION
The mean age of our patients at time of diagnosis was 59.3±16.2 years. Although this age is significantly higher from the mean age reported by
Biyabani8 and Ahsan9 in earlier studies from Pakistan and India,4 this is comparable to the findings
of Yeh11 where the mean age of presentation in the
Asian subgroup was 60.5 years. This may be due
to the fact that majority of our patients were from
an urban population of Karachi where nutritional
status and socioeconomic conditions are generally better compared to other parts of the country
therefore skeletal manifestations were probably
delayed in this cohort. A striking finding in this
study was the unexplained female predominance
(80.6%). This has also been reported in other studies4,9,12 but any causal relationship between gender
and the disease yet remains unknown.
In this series we have demonstrated that in
Pakistan PHPT still presents with overt skeletal
and renal disease. More than half of the patients
(58.3%) sought medical attention because of some
form of musculoskeletal complications such as
bone pain, generalized body aches or proximal
muscle weakness and 12.6% had a fragility fracture
by the time of diagnosis. This degree of severity of
skeletal disease in the Asian population affected
by PHPT has consistently been observed across
various studies from the region.13-15 A study from
India showed that bone pains and painful proximal
myopathy were the commonest presentation (47%),
followed by pathological fractures in 23.5% cases.13
This percentage was even higher in an Iranian study
where (93.5%) patients suffered from bone pains,
deformities, pathologic fractures, and localized bone
tumors.15 Ostietis fibrosa cystica (OFC), the classic
form of skeletal complications of PHPT is now
rarely seen in the developed countries. However,
OFC still remains a predominant presentation of
PHPT in this region.7,8,16 In our study, four patients
(3.8%) had OFC. All of them had a concomitant
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Vitamin D deficiency. This extent of skeletal disease
may partly be attributed to coexisting vitamin D
deficiency as long standing Vitamin D deficiency can
further exaggerate the secretion of PTH. Although
we know that Vitamin D and calcium nutrition
play a role in determination of severity of skeletal
disease but It is yet not clear whether the austerity
of skeletal disease in this region is only because of
hypovitaminosis D and calcium malnutrition or
there are any additional pathogenic environmental
factors or genetic and racial differences playing
a role. This hypothesis is further supported by a
Chinese study which compared BMD in patients
with PHPT in a single Centre from China to that
of USA and noted lower bone mineral density in
Chinese population as compared to USA in patients
with PHPT.14 Same goes for the renal manifestations
the rate of which is higher in Asian population as
compared to the West. Ultrasound abdomen was
done in all patients including those presenting
with abdominal pain to look for renal calculi and
nephrocalcinosis. Renal manifestations were found
in 27.2% of our patients which is comparable to the
findings reported in studies from our region.4,8-10
Further research is required to fully understand the
racial, genetic and environmental factors involved if
any and their potential effects on the clinical profile
of patients in this part of world. Lipase and amylase
were checked in 6(5.8%) patients due to suspicion
of pancreatitis which all turned out to be within
normal range. Overall, 26 (25%) patients reported
having a preexisting diagnosis of depression at the
first clinic visit with the endocrinologist. This high
incidence of depression seen in this cohort, however,
is comparable to the incidence of depression in the
general population of Pakistan and a cause effect
relationship with PHPT could not be established. It
is interesting to note that 22% of the patients were
asymptomatic at presentation and were referred to
the endocrinology service upon incidental finding
of hypercalcemia on their routine health checkup.
Vol. 36 No. 6
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Normocalcemic hyperparathyroidism is a newer
phenotypic variant of PHPT that has evolved
over the last two decades as a result of the routine
evaluation of serum biochemistry in the developed
countries.17,18 Although the dynamics of this entity are
not fully understood at the moment, various studies
have shown that it is not an indolent condition and
patients with normocalcemic hyperparathyroidism
also have an increased prevalence of bone and
renal complications.19-21 Although increasingly
seen in modern day practice, the epidemiology of
normocalcemic primary hyperparathyroidism is
not exactly known,. In a population based study
from Canada, the prevalence was 16.7%.22 In a
study from Lahore, Pakistan, normocalcaemia was
seen in 21.88% of patients.10 However, in our series,
only one patient had normocalcemia. There was
coexistent vitamin D deficiency in this patient and
a history of fragility fracture. It is important to note
that Vitamin D deficiency can cause calcium levels
to fall in the normal range and the normocalcemia
in this situation may not accurately reflect the
gravity of disease as such patients may become
hypercalcemic on correction of Vitamin D levels.
There is also a possibility of missing the diagnosis if
only the absence of hypercalcemia is used to exclude
the diagnosis of PHPT. It is prudent for the clinicians
to understand this interplay of Calcium, Vitamin
D and PTH and that this may have influenced the
disease presentation in our region. The clinicians
should be vigilant to identify and correct Vitamin
D deficiency in PHPT patients before making
treatment decisions. It is also important to mention
here the other end of the paradigm. In the recent
years a trend has been seen among clinicians
in Pakistan to empirically prescribe vitamin D
to patients with musculoskeletal pains without
documenting vitamin D deficiency. This has led to
cases of Vitamin D intoxication and hypercalcemia.
The situation can be critical if this practice is done
in a patient of PHPT23 and implies that Vitamin
D should be checked in all patients suspected of
having PHPT and prescribed only if needed.
There is wide variability in the location of
parathyroid gland and various noninvasive
techniques have been developed for preoperative
localization of disease in order to make the
surgical procedure minimally invasive. The most
widely used and credible modality is Technetium
99 sestamibi and has shown high sensitivity for
pre-operative localization in PHPT.24 Accurate
localization was done in 76.2% of our patients
upon sestamibi scan. Nonetheless, Ultrasound of
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neck was also seen to be an effective localization
tool as it is cheap and readily available in a cost
constrained healthcare system and was able to
localize the lesion in 64.1 % of our patients. Ectopic
location of parathyroid gland in the mediastinum
was detected in four cases.
Surgical excision remains the standard definitive
treatment for PHPT. All patients were offered
surgery as first line treatment, however, one fourth
of patients refused surgery and opted for medical
treatment. Majority of our patients underwent
surgical treatment (76.7%). Excision of the involved
gland was performed in cases where pre-operative
localization was achieved whereas bilateral neck
exploration was performed in the non-localized
cases. However, recurrence of the disease was
seen in 13(12.6%) patients. This may partly be
attributed to the failure to localize the lesion on
pre-operative imaging in nine patients and ectopic
location of parathyroid glands in the mediastinum
in two of them. Median sternotomy was done in
cases of ectopically located parathyroid gland.
Hungry bone syndrome occurred in seven of
our patients post operatively and was managed
without any complications. The low incidence of
post-operative hypocalcemia and hungry bone
syndrome was probably because of the practice in
our Centre to replete Vitamin D in all patients who
are deficient pre operatively. In the Western data, a
significant cases of PHPT are associated with MEN
syndrome,25 however there is no data from Pakistan
regarding PHPT in context of MEN syndrome. To
the best of our knowledge none of our patients had
PHPT associated with MEN syndrome although
genetic testing was not done. It is imperative to
screen all patients presenting with PHPT at age
younger than 40 years for MEN syndromes by
genetic testing. The fact that genetic testing was
not done in our patients who were 40 years of age
or younger reflects the potential lack of awareness
among clinicians about possibility of associated
MEN syndromes in these patients. Clinicians need
to understand the seriousness of this entity and
need to be more vigilant not to miss the diagnosis.
Limitation of this study: It was a single center
study with small number of patients and most of
them from an urban population therefore it may
not reflect the actual picture of the entire Pakistani
population, however it effectively highlights the
morbidity associated with PHPT in our population.
The disease severity may partly appertain to
the delay in seeking medical care due to illiteracy,
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lack of awareness and inaccessibility of healthcare
facilities in a financially constrained population of
this country. The conundrum if this difference in
presentation and disease severity from the West
is only a matter of nutritional and socioeconomic
differences or there are any other genetic factors
playing a role remains to be answered. Targeted
measures like improving patient awareness, routine
calcium screening, vitamin D supplementation
and a high index of suspicion by the clinician may
help in early diagnosis of the condition and thus
reducing morbidity.
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